ArticleFrontiers in veterinary science2025
Tunneling nanotubes provide a new route for bovine viral diarrhea virus spreading.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Cytopathogenic BVDV Core Protein Binds with ASC-Enhance the Assembly of Inflammasome Complex and GSDMD-Mediated Pyroptosis.Veterinary sciences · 2026Article
- BVDV NS5A Binds to CKAP2 and Activates the PI3K/AKT/mTOR Pathway to Facilitate Virus Transmission Through Tunneling Nanotubes.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bovine viral diarrhea virus (BVDV) is one of the major pathogens currently endangering the world's cattle industry. It poses serious difficulties in prevention and treatment because it can infect cattle of all ages and the specific mechanism of its cell-to-cell transmission has not yet been fully clarified. Tunneling nanotubes (TNTs) are F-actin-rich tubules that connect to the cytoplasm of nearby cells. They have been found to play an important role in the transmission of several viruses, but studies on BVDV in TNTs have not been reported. Methods: Firstly, the transwell assay was employed to investigate the transmission routes of BVDV and its capacity to propagate via intercellular junctional structures in the presence of neutralizing antibodies. Secondly, preliminary characterization of these junctional structures was conducted through pharmacological intervention experiments using the microtubule stabilizer paclitaxel, the microtubule disruptor nocodazole, the F-actin disruptors cyclosporine D and spongiosin A, and the gap junction blocker glycine. Subsequently, we validated the composition, spatial positioning, microscopic morphology, and generation characteristics of intercellular junctional structures following BVDV infection. Finally, iSTORM and live-cell fluorescence dynamic imaging techniques, we observed the transmission of BVDV viral particles through TNTs. Results: Transwell assays demonstrated that BVDV can be transmitted via direct intercellular contact, a mode of transmission unaffected by neutralizing antibodies. Pharmacological studies revealed that only the F-actin disruptors spongin A and cell relaxin D inhibited the formation of this structure, preliminarily identifying it as a tunnel nanotube. Validation experiments confirmed that the composition, spatial orientation, microstructure, and formation direction of this connecting structure align with tunneling nanotube characteristics, further substantiating its identity as TNTs. iSTORM and live-cell fluorescence dynamic imaging revealed that BVDV particles can traverse TNTs to complete intercellular infection. Discussion: We first report that BVDV can induce the formation of tunneling nanotubes and exploits this route to spread to uninfected cells. Our data highlight a previously unknown route of BVDV spreading, which could have significant implications for celler transmission and immune evasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.